A Randomized, Double-blind, Placebo-controlled and Open-label, Active Controlled, 4 Period Crossover Trial to Evaluate the Effect of BIA 5 1058 on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Zamicastat (Primary) ; Moxifloxacin
- Indications Cardiovascular disorders; Heart failure; Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors BIAL - Portela C S.A.
- 31 Oct 2019 Status changed from active, no longer recruiting to completed.
- 12 Oct 2018 Planned End Date changed from 1 Sep 2018 to 5 Oct 2018.
- 12 Oct 2018 Status changed from recruiting to active, no longer recruiting.